tubercidin has been researched along with Infarction, Middle Cerebral Artery in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X; Chen, J; Fan, L; Liu, P; Qiu, S; Xu, Y; Yu, L; Zhang, M; Zhang, X | 1 |
| Boison, D; Pignataro, G; Simon, RP | 1 |
2 other study(ies) available for tubercidin and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
EZH2 inhibitor DZNep modulates microglial activation and protects against ischaemic brain injury after experimental stroke.
Topics: Animals; Apoptosis; Disease Models, Animal; Enhancer of Zeste Homolog 2 Protein; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Reperfusion Injury; STAT3 Transcription Factor; Tubercidin; Up-Regulation | 2019 |
Transgenic overexpression of adenosine kinase aggravates cell death in ischemia.
Topics: Adenosine; Adenosine Kinase; Animals; Brain Ischemia; Cell Death; Enzyme Inhibitors; Excitatory Postsynaptic Potentials; Functional Laterality; Hippocampus; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuroprotective Agents; Promoter Regions, Genetic; Pyramidal Cells; Receptor, Adenosine A1; Tubercidin; Ubiquitin | 2007 |